BRIEF—Novartis releases new real-world data for Entresto

Novartis has presented new results from a real-world database study of patients in Germany prescribed Entresto (sacubitril/valsartan) for heart failure with reduced ejection fraction (HFrEF).

The results show a reversed trend of worsening in the New York Heart Association (NYHA) class - a measure of the severity of a patient's heart failure symptoms.

Entresto also reduced levels of NT-proBNP, a blood marker associated with cardiovascular risk in patients with heart failure.

The magnitude of the decrease was similar to that observed in the PARADIGM-HF study.